Shanmuga Hos.

  • Market Cap: Micro Cap
  • Industry: Hospital
  • ISIN: INE0TD301017
  • NSEID:
  • BSEID: 544365
INR
40.80
2.3 (5.97%)
BSENSE

Feb 03

BSE+NSE Vol: 12000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

12.0 k (66.67%) Volume

Shareholding (Sep 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

72.06%

Who are the top shareholders of the Shanmuga Hos.?

06-Jun-2025

The top shareholders of Shanmuga Hos. include Panneerselvam Prabu Sankar with 18.01%, and individual investors who own 24.48%. Notably, there are no pledged promoter holdings, and the largest public shareholder is Black Fox Financial Private Limited with 1.41%.

The top shareholders of Shanmuga Hos. primarily consist of promoters, with Panneerselvam Prabu Sankar holding the largest stake at 18.01%. There are no pledged promoter holdings, indicating a strong commitment from the promoters. In terms of institutional investors, there is one Foreign Institutional Investor (FII) holding a small stake of 0.19%. The highest public shareholder is Black Fox Financial Private Limited, which holds 1.41%. Additionally, individual investors collectively own 24.48% of the company.

Read More

When is the next results date for Shanmuga Hos.?

06-Jun-2025

No Upcoming Board Meetings

Has Shanmuga Hos. declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Shanmuga Hos.?

16-Jul-2025

Peers of Shanmuga Hos. include Lotus Eye Hospital, Fortis Malar, KK Shah Hospital, Global Longlife, Soni Medicare, Sangani Hospital, Aatmaj Health, Nidan Laboratories, and Vaidya Sane. Shanmuga Hos. has excellent management risk and capital structure, but below-average growth, while Soni Medicare leads in 1-year returns at 116.64%.

Peers: The peers of Shanmuga Hos. are Lotus Eye Hospit, Fortis Malar, KK Shah Hospital, Global Longlife, Soni Medicare, Sangani Hospital, Aatmaj Health, Nidan Laborator., and Vaidya Sane.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shanmuga Hos., while Average management risk is found at Lotus Eye Hospit and Global Longlife, and the rest have Below Average management risk. Growth is rated as Below Average for Shanmuga Hos., Lotus Eye Hospit, Fortis Malar, KK Shah Hospital, Global Longlife, Soni Medicare, Sangani Hospital, Nidan Laborator., and Vaidya Sane, while Aatmaj Health has Good growth. Capital Structure is Excellent at Shanmuga Hos. and Good at Lotus Eye Hospit, KK Shah Hospital, Aatmaj Health, Sangani Hospital, and Vaidya Sane, with the rest rated as Below Average.<BR><BR>Return Snapshot: Soni Medicare has the highest 1-year return at 116.64%, while KK Shah Hospital has the lowest at -6.52%, with Shanmuga Hos. not reporting a 1-year return. Additionally, Global Longlife and Nidan Laborator. have negative six-month returns.

Read More

What does Shanmuga Hos. do?

17-Jul-2025

Shanmuga Hospital Ltd is a micro-cap company in the hospital industry, incorporated in 2020 and converted to a public company. It currently reports no sales or profits, with a market cap of INR 63 Cr and key metrics indicating a P/E of 15.00 and a dividend yield of 0.00%.

Overview:<BR>Shanmuga Hospital Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Shanmuga Hospital Ltd was originally incorporated as a Private Limited Company on June 26, 2020, under the name "Shanmuga Hospital Private Limited." It later converted to a Public Company, resulting in a name change to "Shanmuga Hospital Limited." There is no sales or profit data reported for any quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 63 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00<BR>Industry P/E: 59<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.00%<BR>Price-to-Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

How big is Shanmuga Hos.?

24-Jul-2025

As of 24th July, Shanmuga Hospital Ltd has a market capitalization of 65.00 Cr, classified as a Micro Cap. There is no valid data available for recent financial metrics such as Net Sales, Net Profit, Shareholder's Funds, or Total Assets.

As of 24th July, <BR><BR>Market Cap: Shanmuga Hospital Ltd has a market capitalization of 65.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid data available for Net Sales or Net Profit for the latest 4 quarters.<BR><BR>Balance Sheet Snapshot: There is no valid data available for the latest annual period regarding Shareholder's Funds or Total Assets.

Read More

How has been the historical performance of Shanmuga Hos.?

13-Nov-2025

Shanmuga Hos. has shown steady growth in net sales, increasing from 39.34 Cr in Mar'23 to 47.85 Cr in Mar'25, but experienced a decline in operating profit and net income, with profit after tax falling to 4.21 Cr in Mar'25. Despite rising total assets to 52.78 Cr, cash flow from operating activities turned negative at -12.00 Cr in Mar'25.

Answer:<BR>The historical performance of Shanmuga Hos. shows a steady increase in net sales over the past three years, rising from 39.34 Cr in Mar'23 to 43.04 Cr in Mar'24, and reaching 47.85 Cr in Mar'25. The total operating income mirrored this trend, with a consistent increase to 47.85 Cr in Mar'25. However, the operating profit (PBDIT) has seen a slight decline from 8.95 Cr in Mar'24 to 8.47 Cr in Mar'25, despite an increase in other income. Profit before tax also decreased from 7.02 Cr in Mar'24 to 5.69 Cr in Mar'25, leading to a profit after tax of 4.21 Cr in Mar'25, down from 5.25 Cr in Mar'24. The earnings per share (EPS) reflected this decline, dropping to 3.09 in Mar'25 from 5.36 in Mar'24. On the balance sheet, total assets increased significantly from 33.92 Cr in Mar'24 to 52.78 Cr in Mar'25, driven by a rise in cash and bank balances and total reserves. Total liabilities also rose, but at a slower pace, resulting in a stronger equity position with shareholder's funds increasing to 39.70 Cr in Mar'25. Cash flow from operating activities turned negative in Mar'25 at -12.00 Cr, contrasting with a positive cash flow of 9.00 Cr in Mar'24, while financing activities provided a net inflow of 16.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Shanmuga Hos. has demonstrated a positive trend in net sales, which increased from 39.34 Cr in Mar'23 to 47.85 Cr in Mar'25. Despite this growth in revenue, the operating profit (PBDIT) has slightly declined, indicating rising costs, particularly in employee expenses and other expenses, which totaled 39.61 Cr in Mar'25. The profit before tax decreased to 5.69 Cr in Mar'25, resulting in a profit after tax of 4.21 Cr. The company's equity capital and reserves have significantly improved, with total reserves reaching 26.09 Cr in Mar'25, contributing to a total shareholder's fund of 39.70 Cr. The total assets have also increased to 52.78 Cr, primarily due to higher cash and bank balances, while total liabilities rose to 7.61 Cr. However, cash flow from operating activities has turned negative, highlighting potential liquidity challenges despite a positive cash flow from financing activities.

Read More

Is Shanmuga Hos. overvalued or undervalued?

27-Nov-2025

As of November 26, 2025, Shanmuga Hospitals is considered overvalued with a valuation grade of expensive, a PE ratio of 15.44, and an EV to EBITDA of 8.62, despite a recent stock return of 6.87% that outperformed the Sensex.

As of 26 November 2025, the valuation grade for Shanmuga Hospitals has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 15.44, an EV to EBITDA of 8.62, and a ROCE of 12.75%. <BR><BR>When compared to peers, Shanmuga Hospitals' PE ratio is significantly lower than that of Max Healthcare at 80.02 and Apollo Hospitals at 63.6, both of which are classified as very expensive and attractive, respectively. Despite a recent stock return of 6.87% over the past week, which outperformed the Sensex's 0.50%, the overall valuation suggests that Shanmuga Hospitals is not positioned favorably in the current market landscape.

Read More

Why is Shanmuga Hos. falling/rising?

04-Dec-2025

As of 03-Dec, Shanmuga Hospital Ltd's stock price is rising to Rs. 48.10, up 5.14%, supported by strong investor interest and a new all-time high of Rs. 54.9. The stock has outperformed its sector and shows a positive trend, although it exhibits high volatility and a drop in delivery volume.

As of 03-Dec, Shanmuga Hospital Ltd's stock price is rising, currently at Rs. 48.10, reflecting an increase of Rs. 2.35 or 5.14%. This upward movement is supported by several factors. Notably, the stock reached a new 52-week and all-time high of Rs. 54.9 today, indicating strong investor interest. Additionally, the stock has outperformed its sector by 6.04%, suggesting that it is gaining traction compared to its peers.<BR><BR>The stock's performance over the past month has also been positive, with a 13.18% increase, while the benchmark Sensex only rose by 1.34% during the same period. Furthermore, Shanmuga Hospital Ltd is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bullish trend.<BR><BR>However, it is important to note that there are signs of high volatility, with an intraday volatility of 8.8%, and a significant drop in delivery volume by 31.82% compared to the 5-day average, indicating some erratic trading behavior. Despite this, the overall positive performance metrics and the stock's ability to reach new highs contribute to its rising price.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Hospital

stock-summary
Market cap

INR 53 Cr (Micro Cap)

stock-summary
P/E

12.00

stock-summary
Industry P/E

56

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

10.09%

stock-summary
Price to Book

1.26

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.0%
0%
-4.0%
6 Months
-11.3%
0%
-11.3%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Shanmuga Hos. for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News

Is Shanmuga Hos. overvalued or undervalued?

Understanding Shanmuga Hospitals’ Valuation Metrics

Shanmuga Hospitals’ price-to-earnings (PE) ratio stands at 15.44, which is considerably lower than many of its industry peers. For instance, Max Healthcare and Fortis Healthcare exhibit PE ratios well above 70, while Apollo Hospitals, considered an attractive valuation, trades at a PE of around 63.6. This relatively modest PE ratio indicates that Shanmuga Hospitals is priced more conservatively in terms of earnings compared to the broader hospital sector.

Its price-to-book (P/B) ratio of 1.56 also suggests that the stock is trading at a slight premium to its book value, but not excessively so. This contrasts with some peers whose valuations imply a much higher premium, reflecting either stronger growth expectations or...

Read More
Announcements stock-summary

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

09-Jan-2026 | Source : BSE

Certificate pursuant to Regulation 74(5) of SEBI(DP)regulations 2018 for the period from 01.10.2025 to 31.12.2025

Intimation Regarding Commissioning And Operationalisation Of Litho Evo Laser Machine

09-Jan-2026 | Source : BSE

Intimation regarding Commissioning and Operationalisation of Litho Evo Laser Machine

Announcement under Regulation 30 (LODR)-Investor Presentation

28-Nov-2025 | Source : BSE

Investor Presentation under Regulation 30 read with Schedule III of SEBI(LODR) 2015

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
10.30%
EBIT Growth (5y)
-4.74%
EBIT to Interest (avg)
6.69
Debt to EBITDA (avg)
0.90
Net Debt to Equity (avg)
0.14
Sales to Capital Employed (avg)
0.97
Tax Ratio
26.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.75%
ROE (avg)
20.65%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
56
Price to Book Value
1.26
EV to EBIT
9.61
EV to EBITDA
7.09
EV to Capital Employed
1.22
EV to Sales
1.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.75%
ROE (Latest)
10.09%
Technicals key factors
Indicator
Weekly
Monthly
Icon
No records
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Panneerselvam Prabu Sankar (17.95%)

Highest Public shareholder

Black Fox Financial Private Limited (1.38%)

Individual Investors Holdings

24.76%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Shanmuga Hos."
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 5.98% vs -5.65% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 11.05% vs -24.27% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.62",
          "val2": "23.23",
          "chgp": "5.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.54",
          "val2": "3.81",
          "chgp": "19.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.23",
          "val2": "0.29",
          "chgp": "-20.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.01",
          "val2": "1.81",
          "chgp": "11.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.44%",
          "val2": "16.40%",
          "chgp": "2.04%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Shanmuga Hos."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 11.18% vs 9.41% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -19.81% vs 10.29% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.85",
          "val2": "43.04",
          "chgp": "11.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "8.24",
          "val2": "8.60",
          "chgp": "-4.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.63",
          "val2": "0.61",
          "chgp": "3.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.01",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.21",
          "val2": "5.25",
          "chgp": "-19.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "17.22%",
          "val2": "19.98%",
          "chgp": "-2.76%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary
Sep'25
Mar'25
Change(%)
Net Sales
24.62
23.23
5.98%
Operating Profit (PBDIT) excl Other Income
4.54
3.81
19.16%
Interest
0.23
0.29
-20.69%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.01
1.81
11.05%
Operating Profit Margin (Excl OI)
18.44%
16.40%
2.04%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 5.98% vs -5.65% in Mar 2025

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 11.05% vs -24.27% in Mar 2025

Annual Results Snapshot (Standalone) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
47.85
43.04
11.18%
Operating Profit (PBDIT) excl Other Income
8.24
8.60
-4.19%
Interest
0.63
0.61
3.28%
Exceptional Items
0.00
-0.01
100.00%
Standalone Net Profit
4.21
5.25
-19.81%
Operating Profit Margin (Excl OI)
17.22%
19.98%
-2.76%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 11.18% vs 9.41% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is -19.81% vs 10.29% in Mar 2024

stock-summaryCompany CV
About Shanmuga Hospital Ltd stock-summary
stock-summary
Shanmuga Hospital Ltd
Micro Cap
Hospital
Shanmuga Hospital Limited was originally incorporated as a Private Limited Company under the name "Shanmuga Hospital Private Limited" on June 26, 2020. It received a fresh Certificate of Incorporation, from the Registrar of Companies, Central Registration Centre. Subsequently, the status converted into a Public Company, resulting in a name change to "Shanmuga Hospital Limited.
Company Coordinates stock-summary
Icon
No Company Details Available